Literature DB >> 11130998

Primary phagocytic disorders of childhood.

B H Segal1, S M Holland.   

Abstract

Primary phagocytic disorders are rare and usually first manifest during childhood. A phagocytic disorder should be considered in patients with unusually severe or recurrent infections by common pathogens or an infection by certain opportunistic pathogens. Common manifestations of primary phagocytic disorders include recurrent soft-tissue infections requiring incision and drainage, severe dental infections leading to premature tooth loss, recurrent pneumonias, and perirectal infections. Primary phagocytic disorders are caused by defects of neutrophil number or function, and the latter, in turn, can be divided into disorders of oxidative and nonoxidative pathways. Certain phagocytic disorders have unique characteristics apart from the immune defect that may facilitate diagnosis. Early diagnosis of phagocytic disorders can be life-saving or lead to a significant reduction in morbidity and relies on a compatible clinical (or family) history and appropriate laboratory diagnostic studies. Key principles of management of such patients involve early recognition and aggressive treatment of infections and appropriate surgical débridement of localized disease. Prophylactic antibiotics, BMT, and the use of exogenous cytokines, such as IFN-gamma and G-CSF, are appropriate for specific phagocytic disorders. Gene therapy is a promising strategy for several of the phagocytic disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130998     DOI: 10.1016/s0031-3955(05)70273-x

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  5 in total

1.  Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Authors:  Carly G Dennis; William R Greco; Yseult Brun; Richard Youn; Harry K Slocum; Ralph J Bernacki; Russell Lewis; Nathan Wiederhold; Steven M Holland; Ruta Petraitiene; Thomas J Walsh; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.

Authors:  S Seyedmousavi; Y C Chang; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Enhancement of neutrophil autophagy by an IVIG preparation against multidrug-resistant bacteria as well as drug-sensitive strains.

Authors:  Hiroshi Itoh; Hidemasa Matsuo; Naoko Kitamura; Sho Yamamoto; Takeshi Higuchi; Hiromu Takematsu; Yasuhiko Kamikubo; Tadakazu Kondo; Kouhei Yamashita; Masataka Sasada; Akifumi Takaori-Kondo; Souichi Adachi
Journal:  J Leukoc Biol       Date:  2015-04-23       Impact factor: 4.962

4.  Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung.

Authors:  Seyedmojtaba Seyedmousavi; Michael J Davis; Janyce A Sugui; Tzvia Pinkhasov; Shannon Moyer; Andres M Salazar; Yun C Chang; Kyung J Kwon-Chung
Journal:  MBio       Date:  2018-03-27       Impact factor: 7.867

5.  Functional Characterization of Clinical Isolates of the Opportunistic Fungal Pathogen Aspergillus nidulans.

Authors:  Rafael Wesley Bastos; Clara Valero; Lilian Pereira Silva; Taylor Schoen; Milton Drott; Verônica Brauer; Rafael Silva-Rocha; Abigail Lind; Jacob L Steenwyk; Antonis Rokas; Fernando Rodrigues; Agustin Resendiz-Sharpe; Katrien Lagrou; Marina Marcet-Houben; Toni Gabaldón; Erin McDonnell; Ian Reid; Adrian Tsang; Berl R Oakley; Flávio Vieira Loures; Fausto Almeida; Anna Huttenlocher; Nancy P Keller; Laure Nicolas Annick Ries; Gustavo H Goldman
Journal:  mSphere       Date:  2020-04-08       Impact factor: 4.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.